Compositions of nicardipine and sulfoalkylated β-cyclodextrin
Compositions of an inclusion complex of nicardipine or a pharmaceutically acceptable salt thereof and a sulfoalkylated β-cyclodextrin. The compositions being formulated for parenteral bolus administration to a human subject. The compositions being useful in the treatment of cardiovascular and cerebrovascular disorders.
1. A pharmaceutical composition comprising an aqueous solution comprising an inclusion complex of nicardipine or a pharmaceutically acceptable salt thereof, a buffering agent and a sulfoalkylated β-cyclodextrin,
wherein the composition is premixed and is formulated for direct parenteral bolus administration for immediate use without dilution to a human subject, and wherein a pH of the composition is 4.5 to 5.5,
wherein the composition is in unit dose format and the unit dose contains the formulation in a volume of from 0.5 to 20 ml,
wherein the nicardipine concentration is 0.5 mg/ml, and
wherein the sulfoalkylated β-cyclodextrin in the pharmaceutical composition is from 2% to 5% (w/v) wherein the sulfoalkylated β-cyclodextrin is a sulfobutylated β-cyclodextrin having an average of 5 to 8 degrees of sulfobutylation.
2. The pharmaceutical composition of claim 1 , wherein the sulfobutylated β-cyclodextrin is sulfobutylether β-cyclodextrin.
3. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable salt of nicardipine is the nicardipine hydrochloride salt.
4. The pharmaceutical composition of claim 1 , comprising the pharmaceutically acceptable salt of nicardipine in a parenterally injectable aqueous carrier, wherein the concentration of the buffering agent in the composition is 0.1 mM to 100 mM.
5. The pharmaceutical composition of claim 4 , wherein the sulfoalkylated β-cyclodextrin is a sulfobutylated β-cyclodextrin having an average of 7 degrees of sulfobutylation.
6. The pharmaceutical composition of claim 4 , wherein the buffering agent comprises at least one agent selected from a group consisting of acetate, citrate, succinate, and phosphate.
7. The pharmaceutical composition of claim 4 , further comprising a tonicity adjusting agent.
8. The pharmaceutical composition of claim 4 , wherein the composition further comprises at least one co-solvent in a concentration of 0.1 to 25% (w/v).
9. The pharmaceutical composition of claim 8 , wherein concentration of at least one co-solvent is 0.1 to 10% (w/v).
10. The pharmaceutical composition of claim 4 , wherein the pH is above a pH of 4.5 and equal to or less than a pH of 5.5.